BidaskClub upgraded shares of SAGE Therapeutics (NASDAQ:SAGE) from a sell rating to a hold rating in a research note released on Wednesday, BidAskClub reports.

Other equities research analysts have also issued research reports about the company. JPMorgan Chase & Co. reaffirmed a buy rating on shares of SAGE Therapeutics in a research report on Wednesday, July 24th. Wedbush began coverage on SAGE Therapeutics in a research report on Wednesday, May 22nd. They set an outperform rating and a $207.00 price target on the stock. Oppenheimer dropped their target price on SAGE Therapeutics from $200.00 to $190.00 and set an outperform rating on the stock in a research report on Wednesday, August 7th. Finally, William Blair reissued a buy rating on shares of SAGE Therapeutics in a research report on Wednesday, July 24th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $200.27.

NASDAQ SAGE opened at $165.33 on Wednesday. The company has a quick ratio of 16.00, a current ratio of 16.00 and a debt-to-equity ratio of 0.03. The stock’s 50-day moving average is $163.97 and its 200-day moving average is $168.30. SAGE Therapeutics has a one year low of $79.88 and a one year high of $193.56.

SAGE Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($3.28) EPS for the quarter, topping the Zacks’ consensus estimate of ($3.32) by $0.04. The business had revenue of $0.87 million for the quarter, compared to analyst estimates of $0.27 million. The company’s revenue for the quarter was down 99.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.36) EPS. On average, equities research analysts forecast that SAGE Therapeutics will post -13.33 EPS for the current year.

In related news, Director James M. Frates sold 8,000 shares of SAGE Therapeutics stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $160.58, for a total value of $1,284,640.00. The sale was disclosed in a document filed with the SEC, which is available at this link. 4.60% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of SAGE. Aperio Group LLC increased its holdings in SAGE Therapeutics by 37.0% during the 2nd quarter. Aperio Group LLC now owns 7,515 shares of the biopharmaceutical company’s stock valued at $1,376,000 after purchasing an additional 2,030 shares during the period. L & S Advisors Inc lifted its holdings in shares of SAGE Therapeutics by 11.5% during the 2nd quarter. L & S Advisors Inc now owns 5,845 shares of the biopharmaceutical company’s stock valued at $1,070,000 after purchasing an additional 605 shares in the last quarter. DekaBank Deutsche Girozentrale lifted its holdings in shares of SAGE Therapeutics by 127.4% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 49,944 shares of the biopharmaceutical company’s stock valued at $8,233,000 after purchasing an additional 27,980 shares in the last quarter. Arden Trust Co bought a new position in shares of SAGE Therapeutics during the 2nd quarter valued at about $279,000. Finally, Metropolitan Life Insurance Co NY lifted its holdings in shares of SAGE Therapeutics by 5.0% during the 1st quarter. Metropolitan Life Insurance Co NY now owns 3,670 shares of the biopharmaceutical company’s stock valued at $583,000 after purchasing an additional 174 shares in the last quarter.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

Featured Story: Market Capitalization

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.